New Stock News | Chenyi Biologicals' Hong Kong IPO Prospectus Invalid
Chengyi Bio Cayman Limited (referred to as "Chengyi Bio") submitted its Hong Kong stock prospectus on October 8, 2025, which expired on April 8, 2026, after 6 months.
Chengyi Bioscience Cayman Limited (referred to as "Chengyi Bioscience") submitted its Hong Kong IPO prospectus on October 8, 2025, valid for 6 months until April 8, 2026, with Jefferies, BofA Securities, and CICC as its joint sponsors.
According to the previous prospectus, Chengyi Bioscience is a global biotechnology company in the clinical stage, dedicated to exploring and developing a new generation of oral small molecule drugs to address significant unmet medical needs in the global cardiovascular metabolism and inflammatory disease areas. The company leverages its proprietary TRANDD platform, with a product pipeline tailored for both monotherapy and combination therapy, aiming to achieve effective results in weight management (obesity/overweight), metabolic associated fatty liver disease ("MASH"), osteoarthritis ("OA") pain, and other cardiovascular metabolic diseases.
Related Articles
Guotai Haitong: The U.S. Q1 economy is showing an upward K-shaped pattern with "inflation without stagnation", and the threshold of interest rate sensitivity has increased, causing a bottom upshift in U.S. bond yields.
April PMI shows that companies are increasing precautionary stockpiling, CMSC: pay attention to the input effects of the Middle East situation and the implementation of policies to expand domestic demand.
The dream of the "super app" by Walt Disney Company (DIS.US) has been reignited by the new CEO.
Guotai Haitong: The U.S. Q1 economy is showing an upward K-shaped pattern with "inflation without stagnation", and the threshold of interest rate sensitivity has increased, causing a bottom upshift in U.S. bond yields.
April PMI shows that companies are increasing precautionary stockpiling, CMSC: pay attention to the input effects of the Middle East situation and the implementation of policies to expand domestic demand.
The dream of the "super app" by Walt Disney Company (DIS.US) has been reignited by the new CEO.
